Neurological

Official Title A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis

Purpose

The purpose of this study is to evaluate the long-term safety and tolerability of a drug (ALKS 8700) used to treat adults with Relapsing Remitting Multiple Sclerosis.

Could this study be right for you?

You may be eligible for this study if you:
- are between 18 and 65 years of age
- have a confirmed diagnosis of Relapsing Remitting Multiple Sclerosis
- EDSS score of 0.0-6.0 at screening and visit 2

Age Range

18 and up

Official Title AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

Purpose

The purpose of this study is to determine exactly how the drug Ocrelizumab interacts with human cells to produce its intended effect in those with Relapsing Multiple Sclerosis (RMS).

Could this study be right for you?

You may be eligible for this study if you:
- have been diagnosed with Relapsing Multiple Sclerosis
- have an EDSS score of 0-5.5, inclusive, at screening, and a disease duration less than 15 years if EDSS > 5.0
- are either treatment-naïve or receiving treatment with disease-modifying therapies
- have had at least one clinically documented relapse in the past year and/or at least one T1-weighted Gd- enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment

Age Range

18 and up